Unique Positive Cooperativity Between the fi-Arrestin-Biased β-Blocker Carvedilol and a Small Molecule Positive Allosteric Modulator of the β2-Adrenergic Receptor

Among fi-blockers that are clinically prescribed for heart failure, carvedilol is a first-choice agent with unique pharmacological properties. Carvedilol is distinct from other fi-blockers in its ability to elicit fi-arrestin-biased agonism, which has been suggested to underlie its cardioprotective effects. Augmenting the pharmacologic properties of carvedilol thus holds the promise of developing more efficacious and/or biased fi-blockers. We recently identified compound 6 (cmpd-6), the first small molecule positive allosteric modulator of the fi2-adrenergic receptor (fi2AR). Cmpd-6 is positively cooperative with orthosteric agonists at the fi2AR and enhances agonistmediated transducer (G-protein and fi-arrestin) signaling in an unbiased manner. Here, we report that cmpd-6, quite unexpectedly, displays strong positive cooperativity only with carvedilol among a panel of structurally diverse fi-blockers. Cmpd-6 enhances the binding affinity of carvedilol for the fi2AR and augments its ability to competitively antagonize agonist-induced cAMP generation. Cmpd-6 potentiates fi-arrestin1- but not Gs-protein-mediated high-affinity binding of carvedilol at the fi2AR and fi-arrestin-mediated cellular functions in response to carvedilol including extracellular signal-regulated kinase phos-phorylation, receptor endocytosis, and trafficking into lysosomes. Importantly, an analog of cmpd-6 that selectively retains positive cooperativity with carvedilol acts as a negative modulator of agonist-stimulated fi2AR signaling. These unprecedented cooperative properties of carvedilol and cmpd-6 have implications for fundamental understanding of G-protein-coupled receptor (GPCR) allosteric modulation, as well as for the development of more effective biased beta blockers and other GPCR therapeutics. SIGNIFICANCE STATEMENT This study reports on the small molecule-mediated allosteric modulation of the fi-arrestin-biased fi-blocker, carvedilol. The small molecule, compound-6 (cmpd-6), displays an exclusive positive cooperativity with carvedilol among other fi-blockers and enhances the binding affinity of carvedilol for the fi2-adrenergic receptor. Cooperative effects of cmpd-6 augment the fi-blockade property of carvedilol while potentiating its fi-arrestin-mediated signaling functions. These findings have potential implications in advancing G-protein-coupled receptor allostery, developing biased therapeutics and remedying cardiovascular ailments.

Automated summary

Carvedilol is a first-choice agent for heart failure treatment with unique pharmacological properties, and compound-6 (cmpd-6) displays exclusive positive cooperativity with carvedilol among other fi-blockers. This cooperative effect enhances the binding affinity of carvedilol for the fi2-adrenergic receptor, potentially improving the efficacy of biased beta blockers and other GPCR therapeutics.